WeVote

Bill

Bill

HB 3086

Relating to requirements for pharmaceutical drug manufacturers to report prescription drug costs.

89th Legislature (2025) Introduced by Tom Oliverson

Texas would require drug manufacturers to disclose prescription drug pricing data to state regulators, increasing transparency into pharmaceutical cost structures and pricing practices.

Referred to Public Health
0
WeVote Research Nonpartisan
Bill Summary · HB 3086

Legislative bill overview

HB 3086 would require pharmaceutical drug manufacturers to report prescription drug costs and pricing information to the state of Texas. The bill establishes transparency requirements for manufacturers to disclose data about their drug pricing practices, potentially giving state regulators and policymakers better visibility into cost drivers in the pharmaceutical market.

Why is this important

Prescription drug costs are a major concern for consumers, insurers, and state budgets. Increased transparency about manufacturer pricing could inform policy decisions, help identify price increases, and potentially support efforts to negotiate better drug prices for state programs like Medicaid. However, this information is currently largely proprietary and controlled by manufacturers.

Potential points of contention

  • Proprietary business information: Manufacturers may resist disclosure requirements, arguing that pricing strategies and cost data are trade secrets that provide competitive advantages
  • Enforcement and compliance mechanisms: The bill's effectiveness depends on how the state will monitor compliance, investigate non-compliance, and what penalties exist for manufacturers who don't report accurately
  • Federal preemption concerns: Pharmaceutical regulation is heavily federalized; manufacturers may challenge whether Texas has authority to impose independent reporting requirements that differ from federal frameworks

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.